On August 28, 2023, Thorne HealthTech, Inc., a Delaware corporation (the Company or
Thorne), issued a press release announcing the execution of an Agreement and Plan of Merger (the Merger Agreement) with Healthspan Buyer, LLC (Parent) and Healthspan Merger Sub, Inc. (Purchaser, and
together with Parent, the Buyer Parties). The Buyer Parties are affiliated funds of L Catterton.
The Merger Agreement provides that,
upon the terms and subject to the conditions thereof, Purchaser will commence a tender offer (the Offer) to acquire any and all shares of common stock of the Company, $0.01 par value per share, at a price per share of $10.20 in cash,
without interest and subject to applicable withholding taxes.
This Schedule 14D-9 filing consists of the
following documents related to the proposed Offer:
|
|
|
(i) |
|
Press Release, dated as of August 28, 2023 (Exhibit 99.1) |
(ii) |
|
Letter to Employees, first used August 28, 2023 (Exhibit 99.2) |
(iii) |
|
Letter to Customers, first used August 28, 2023 (Exhibit 99.3) |
(iv) |
|
Letter to Vendors, first used August 28, 2023 (Exhibit 99.4) |
(v) |
|
Transcript of Employee Town Hall, August 28, 2023 (Exhibit 99.5) |
The information set forth under Items 1.01 and 8.01 of Thornes Current Report on Form
8-K filed by the Company on August 28, 2023 (including all exhibits attached thereto) is incorporated herein by reference.
Additional Information and Where to Find It
In
connection with the proposed acquisition of Thorne, Purchaser will commence a tender offer for all of the outstanding shares of Thorne. The tender offer has not yet commenced. This communication is for informational purposes only and is neither an
offer to purchase nor a solicitation of an offer to sell any securities of Thorne. It is also not a substitute for the tender offer materials that Purchaser will file with the Securities and Exchange Commission (the SEC) upon
commencement of the tender offer. The solicitation and offer to buy the outstanding shares of Thorne will only be made pursuant to an offer to purchase and related tender offer materials. At the time of the commencement of the tender offer,
Purchaser will file tender offer materials on Schedule TO with the SEC, and Thorne will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER
OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED
BY THORNES STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer materials and the solicitation/recommendation statement will be made available to Thornes stockholders free of charge. A free
copy of the tender offer materials and the solicitation/recommendation statement will also be made available to Thornes stockholders by visiting Thornes website (https://investors.thornehealthtech.com/). In addition, the tender offer
materials and the solicitation/recommendation statement (and all other documents filed by Thorne with the SEC) will be available free of charge on the SECs website (http://www.sec.gov) upon filing with the SEC. THORNES STOCKHOLDERS ARE
ADVISED TO READ THE TENDER OFFER MATERIALS AND THE SOLICITATION/RECOMMENDATION STATEMENT, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED BY PURCHASER OR THORNE WITH THE SEC WHEN THEY BECOME AVAILABLE
BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER. THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TENDER OFFER, PURCHASER AND THORNE.
Forward-Looking Statements
This communication contains
forward-looking statements. All statements other than statements of historical facts contained in this communication are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may,
will, should, would, expect, plan, anticipate, could, intend, target, project, contemplate, believe,
estimate, predict, potential or continue or the negative of these terms or other similar expressions. Forward-looking statements contained in this communication include, but are not limited to,
statements regarding Thornes pending acquisition by L Catterton or its affiliates (the Transaction), including the expected timing of the closing of the Transaction and considerations taken into account by Thornes
Special Committee of the Board of Directors and Thornes Board of Directors in approving the Transaction. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of
Thornes assumptions prove incorrect, Thornes actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include the risk that the conditions to the
tender offer or the closing of the Transaction are not satisfied, including the risk that a sufficient number of Thornes stockholders do not tender their shares into the tender offer or otherwise participate in the Transaction; risks
associated with potential litigation relating to the Transaction; uncertainties as to the timing of the consummation of the